Aktuelle Neurologie, Table of Contents Aktuelle Neurologie 2012; 39(07): 383-384DOI: 10.1055/s-0032-1305280 Kompetenznetz Multiple Sklerose © Georg Thieme Verlag KG Stuttgart · New YorkAktuelles aus der Forschung Authors Author Affiliations T. Korn S. G. Meuth 2 Klinik und Poliklinik für Neurologie, Abteilung für Entzündliche Erkrankungen des Nervensystems und Neuroonkologie, Universitätsklinikum Münster Recommend Article Abstract Buy Article(opens in new window) Full Text References Literatur 1 Markoullis K, Sargiannidou I, Schiza N et al. Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 2012; 123: 873-886 2 Youssef S, Stüve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84 3 Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725-733 4 Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608 5 Waubant E, Pelletier D, Mass M et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study. Neurology 2012; 78: 1171-1178 6 Axtell RC, de Jong BA, Boniface K et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010; 16: 406-412 7 Clanet M, Radue EW, Kappos L et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-1517 8 Bushnell SE, Zhao Z, Stebbins CC et al. Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsing-remitting MS. Neurology 2012; (E-pub ahead of print) 9 Gregory AP, Dendrou CA, Attfield KE et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012; (E-pub ahead of print) 10 Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46 11 Weishaupt A, Jander S, Bruck W et al. Molecular mechanisms of high-dose antigen therapy in experimental autoimmune encephalomyelitis: rapid induction of Th1-type cytokines and inducible nitric oxide synthase. J Immunol 2000; 165: 7157-63 12 Arnett HA, Mason J, Marino M et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4: 1116-1122 13 The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465
